Account-creators
1,040
edits
Difference between revisions of "Diffuse tenosynovial giant-cell tumour"
Jump to navigation
Jump to search
Diffuse tenosynovial giant-cell tumour (view source)
Revision as of 09:54, 10 October 2019
, 09:54, 10 October 2019→Molecular: ENLIVEN study
Jensflorian (talk | contribs) (→Molecular: ENLIVEN study) |
|||
| Line 88: | Line 88: | ||
==Molecular== | ==Molecular== | ||
*Clonal - overexpresses CSF1.<ref name=pmid22849738>{{Cite journal | last1 = Lucas | first1 = DR. | title = Tenosynovial giant cell tumor: case report and review. | journal = Arch Pathol Lab Med | volume = 136 | issue = 8 | pages = 901-6 | month = Aug | year = 2012 | doi = 10.5858/arpa.2012-0165-CR | PMID = 22849738 }}</ref> | *Clonal - overexpresses CSF1.<ref name=pmid22849738>{{Cite journal | last1 = Lucas | first1 = DR. | title = Tenosynovial giant cell tumor: case report and review. | journal = Arch Pathol Lab Med | volume = 136 | issue = 8 | pages = 901-6 | month = Aug | year = 2012 | doi = 10.5858/arpa.2012-0165-CR | PMID = 22849738 }}</ref> | ||
**Possible treatment with CSF1-R inhibitor Pexidartinib.<ref>{{Cite journal | last1 = Tap | first1 = WD. | last2 = Gelderblom | first2 = H. | last3 = Palmerini | first3 = E. | last4 = Desai | first4 = J. | last5 = Bauer | first5 = S. | last6 = Blay | first6 = JY. | last7 = Alcindor | first7 = T. | last8 = Ganjoo | first8 = K. | last9 = Martín-Broto | first9 = J. | title = Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. | journal = Lancet | volume = 394 | issue = 10197 | pages = 478-487 | month = 08 | year = 2019 | doi = 10.1016/S0140-6736(19)30764-0 | PMID = 31229240 }}</ref> | |||
==Sign out== | ==Sign out== | ||